GlassScriptPhysician profile
Katrina Jane Platt
NPI 1871749556
$5,147.31
in general payments reported to CMS, 2019-2025
24 companies · $832 in 2025
The $832 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $611 · 2021: $612 · 2022: $42.70 · 2023: $1,146 · 2024: $1,235 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,212.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,468.50 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Ams 700, Accolade Sr |
| Janssen Pharmaceuticals, INC | $872.36 | 2020-2024 | Xarelto |
| Abbvie INC. | $614.52 | 2024-2025 | |
| Abiomed | $383.29 | 2024 | Impella |
| Medtronic, INC. | $268.01 | 2025 | Micra, Linq II, Tyrx |
| Amgen INC. | $229.98 | 2019-2023 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $160.57 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Novo Nordisk INC | $134.20 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $123.49 | 2025 | |
| Amarin Pharma, INC. | $109.20 | 2020-2021 | |
| Medtronic USA, INC. | $107.51 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $92.91 | 2021 | |
| Arbor Pharmaceuticals, INC. | $68.47 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $43.91 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $40.04 | 2020-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $38.28 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.49 | 2020 | |
| Allergan, INC. | $34.47 | 2020 | |
| Cardiva Medical, INC. | $24.18 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Almatica Pharma LLC | $23.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.74 | 2024 | |
| Glaxosmithkline, LLC. | $19.39 | 2020 | |
| Therapeuticsmd, INC. | $18.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Platt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.